v3.7.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended 9 Months Ended
Jul. 31, 2017
Jul. 31, 2016
Jul. 31, 2017
Jul. 31, 2016
Revenue $ 362,500 $ 100,000 $ 362,500 $ 100,000
Operating costs and expenses:        
Litigation and licensing expenses 8,551 2,022 83,713
Inventor royalties and contingent legal fees 141,451 61,720 141,451 61,720
Amortization of patents 81,325 81,324 243,973 243,972
Research and development expenses (including non-cash stock option compensation expenses of $64,705, $84,316,$213,333 and $171,241, respectively) 362,968 292,063 1,245,722 1,142,973
Marketing, general and administrative expenses (including non-cash stock option compensation expenses of $416,411, $156,125, $719,440 and $398,949 respectively) 1,507,681 631,226 3,067,235 2,163,332
Total operating costs and expenses 2,093,425 1,074,884 4,700,403 3,695,710
Loss from operations (1,730,925) (974,884) (4,337,903) (3,595,710)
Gain on extinguishment of patent acquisition obligation (Note 6) 1,547,608
Interest expense (71,667) (132,357) (442,693) (383,238)
Interest income 8,192 3,466 9,817 10,190
Loss before income taxes (1,794,400) (1,103,775) (3,223,171) (3,968,758)
Provision for income taxes
Net loss (1,794,400) (1,103,775) (3,223,171) (3,968,758)
Deemed dividend to preferred stockholder (Note 7) (2,008,775)
Net loss attributable to common stockholders $ (1,794,400) $ (1,103,775) $ (5,231,946) $ (3,968,758)
Net loss per common share:        
Basic and diluted (in Dollars per share) $ (0.12) $ (0.13) $ (0.47) $ (0.45)
Weighted average common shares outstanding:        
Basic and diluted (in Shares) 14,561,754 8,745,423 11,030,992 8,736,167

Source